After a thorough and comprehensive review of proposals received from suppliers of viral marker testing platforms and assays, CTS has decided to convert to the Ortho VERSEIA Integrated Processor (VIP) viral marker testing platform and associated assays in January 2021. An exact conversion date will be provided when available. We are confident that the VERSIA system will allow us to continue delivering on our commitment to support our clients in their life-saving mission.
Read all about it on the Communication page by clicking this link: Communications
CTS successfully implemented Donor-Screen HLA® Class I and II testing on the Stratec Biomedical ...
CTS received notification from Sanochemia Pharmazeutika AG of their intent to immediately discontinu...
Reminder: On Wednesday August 15, 2018 at 11:00AM PDT, we will be hosting a webinar regarding the ch...
CTS Spotlight at 2018 AABB Annual Meeting Sunday, October 14, 2018 at 1:30 PM: Scientific Oral ...
The new Learning Center website launch today on Monday, March 30, 2020. While the link to the new Le...
The CTS forms listed below have been revised with an implementation date of September 2, 2019. ...